News & Updates

Individuals with acute COVID-19 who receive prompt antiviral treatment, such as ensitrelvir, nirmatrelvir, or molnupiravir, in the outpatient setting may be less likely to experience post–COVID-19 condition (PCC) compared with those who receive no treatment.

Perioperative adebrelimab plus chemotherapy improves event-free survival (EFS) and major pathological response (MPR) in individuals with resectable stage II/III non-small cell lung cancer (NSCLC) in an interim analysis.

Treatment with colchicine and famotidine plus loratadine, in addition to specialist supportive care, can substantially ease severe fatigue among patients suffering from long COVID, as shown by the results of the STIMULATE ICP trial.

Part 2 of the HAPPEN* trial shows a 60-percent reduction in the incidence of non-ventilator–associated hospital-acquired pneumonia (NV-HAP) among hospitalized patients with improved oral hygiene.